Capricor Therapeutics Inc
CAPR7.320USD
-0.580-7.35%
交易中 （美东）报价延迟15分钟
334.34M总市值
亏损市盈率 TTM
关于 Capricor Therapeutics Inc 公司
Capricor Therapeutics, Inc. 是一家生物技术公司，致力于开发转化细胞和外泌体疗法，用于治疗和预防罕见疾病。该公司的项目专注于开发和商业化由心脏球衍生细胞 (CDC) 组成的细胞治疗技术，用于治疗杜氏肌营养不良症 (DMD)。其主要候选产品 CAP-1002 是一种同种异体心脏衍生细胞疗法。CAP-1002 正在进行 3 期临床开发，用于治疗杜氏肌营养不良症 (DMD)。CAP-1002 具有专门针对肌营养不良症和心脏病的免疫调节、抗纤维化和再生作用。该公司利用其外泌体技术，使用其 StealthX 平台进行临床前开发，专注于疫苗学、寡核苷酸、蛋白质和小分子疗法的靶向递送领域，以治疗和预防多种疾病。
公司简介
公司代码CAPR
公司名称Capricor Therapeutics Inc
上市日期Jun 04, 2002
CEODr. Linda Marban, Ph.D.
员工数量160
证券类型Ordinary Share
年结日Jun 04
公司地址10865 Road to the Cure
城市SAN DIEGO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编92121
电话13103583200
网址https://capricor.com/
公司代码CAPR
上市日期Jun 04, 2002
CEODr. Linda Marban, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
+6.26%
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
8.22K
+43.68%
Michael Binks
Michael Binks
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
Dr. Paul Auwaerter, M.D.
Dr. Paul Auwaerter, M.D.
Independent Director
Independent Director
--
--
Ms. Karimah Es Sabar
Ms. Karimah Es Sabar
Independent Director
Independent Director
--
--
Ms. Karen G. Krasney, J.D.
Ms. Karen G. Krasney, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
+6.26%
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
8.22K
+43.68%
Michael Binks
Michael Binks
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 6月7日 周六
更新时间: 6月7日 周六
持股股东
股东类型
持股股东
持股股东
占比
Nippon Shinyaku Co Ltd
15.51%
BlackRock Institutional Trust Company, N.A.
5.89%
The Vanguard Group, Inc.
5.04%
Farallon Capital Management, L.L.C.
4.92%
State Street Global Advisors (US)
4.03%
Other
64.60%
持股股东
持股股东
占比
Nippon Shinyaku Co Ltd
15.51%
BlackRock Institutional Trust Company, N.A.
5.89%
The Vanguard Group, Inc.
5.04%
Farallon Capital Management, L.L.C.
4.92%
State Street Global Advisors (US)
4.03%
Other
64.60%
股东类型
持股股东
占比
Investment Advisor
16.88%
Corporation
15.51%
Investment Advisor/Hedge Fund
10.46%
Hedge Fund
9.89%
Research Firm
3.18%
Individual Investor
1.28%
Bank and Trust
0.30%
Pension Fund
0.22%
Venture Capital
0.21%
Other
42.06%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
249
26.45M
57.87%
+1.42M
2025Q1
248
26.31M
57.59%
+1.55M
2024Q4
207
25.12M
55.44%
+10.37M
2024Q3
154
16.01M
37.60%
+3.34M
2024Q2
126
9.07M
28.24%
-1.39M
2024Q1
98
7.40M
24.60%
-337.42K
2023Q4
80
6.78M
23.62%
+312.08K
2023Q3
81
6.27M
24.30%
+2.56M
2023Q2
82
3.34M
13.02%
-283.03K
2023Q1
82
3.13M
12.44%
-2.22M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Nippon Shinyaku Co Ltd
7.09M
15.51%
+4.94M
+230.41%
Sep 20, 2024
BlackRock Institutional Trust Company, N.A.
2.69M
5.89%
-69.04K
-2.50%
Mar 31, 2025
The Vanguard Group, Inc.
2.26M
4.94%
-12.79K
-0.56%
Mar 31, 2025
Farallon Capital Management, L.L.C.
2.25M
4.92%
--
--
Mar 31, 2025
State Street Global Advisors (US)
1.84M
4.03%
-365.57K
-16.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
901.38K
1.97%
+21.91K
+2.49%
Mar 31, 2025
Morgan Stanley & Co. LLC
735.10K
1.61%
+164.73K
+28.88%
Mar 31, 2025
Woodline Partners LP
729.32K
1.6%
+99.38K
+15.78%
Mar 31, 2025
Citadel Advisors LLC
415.95K
0.91%
+150.71K
+56.82%
Mar 31, 2025
UBS Financial Services, Inc.
393.34K
0.86%
+270.52K
+220.26%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Neuroscience and Healthcare ETF
0.98%
Virtus LifeSci Biotech Clinical Trials ETF
0.64%
Simplify Propel Opportunities ETF
0.59%
ALPS Medical Breakthroughs ETF
0.31%
Hypatia Women CEO ETF
0.15%
SPDR S&P Biotech ETF
0.12%
iShares Micro-Cap ETF
0.09%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
Vanguard US Momentum Factor ETF
0.07%
iShares Russell 2000 Growth ETF
0.03%
查看更多
iShares Neuroscience and Healthcare ETF
占比0.98%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.64%
Simplify Propel Opportunities ETF
占比0.59%
ALPS Medical Breakthroughs ETF
占比0.31%
Hypatia Women CEO ETF
占比0.15%
SPDR S&P Biotech ETF
占比0.12%
iShares Micro-Cap ETF
占比0.09%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.07%
Vanguard US Momentum Factor ETF
占比0.07%
iShares Russell 2000 Growth ETF
占比0.03%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
